Literature DB >> 24163686

Location of the Susceptibility Vessel Sign on T2*-Weighted MRI and Early Recanalization within 1 Hour after Tissue Plasminogen Activator Administration.

Junya Aoki1, Kazumi Kimura, Kensaku Shibazaki, Yuki Sakamoto, Naoki Saji, Junichi Uemura.   

Abstract

BACKGROUND: We have recently reported that the susceptibility vessel sign (SVS) at the proximal portion of the horizontal (M1) middle cerebral artery (MCA) on T2*-weighted MRI is a strong predictor for no early recanalization after intravenous recombinant tissue plasminogen activator (t-PA) therapy. However, it is unclear whether the presence of the SVS at other locations, such as distal M1, the vertical portion (M2) of the MCA, and distal branches (MCA distal), is a predictor for no early recanalization in acute ischemic stroke patients.
METHODS: The SVS was defined as a hypointense signal of the MCA on T2*-weighted MRI on admission. The locations of the SVS were classified as M1 proximal, M1 distal, and MCA distal. M1 proximal SVS was defined as an SVS at the origin of the M1. M1 distal SVS was any M1 SVS not including the origin of the M1. MCA distal SVS was an SVS further away from M1. Early recanalization was defined as a new appearance of at least one of the distal branches on MRA within 1 h after t-PA therapy. A good outcome at 3 months was defined as a modified Rankin Scale (mRS) score of 0-1.
RESULTS: Consecutive acute stroke patients admitted to our stroke center and treated with t-PA between October 2005 and October 2012 were enrolled. There were 158 patients [median age, 78 (71-84) years; 84 (53%) males; median National Institutes of Health Stroke Scale score, 16 (10-20)]. Internal carotid artery occlusion was seen in 18 (72%) of the 25 patients with M1 proximal SVS, in 3 (14%) of the 22 patients with M1 distal SVS, in 4 (9%) of the 44 patients with MCA distal SVS, and in 18 (27%) of the 67 patients with No SVS (p < 0.001). Twenty-four (96%) of the 25 patients with M1 proximal SVS had no early recanalization, while 16 (73%) of the 22 patients with M1 distal SVS, 25 (57%) of the 44 patients with MCA distal SVS, and 36 (54%) of the 67 patients with No SVS had no early recanalization (p < 0.001, 0.140, and 0.846, respectively, compared to the patients with No SVS). Multivariate analysis showed that only M1 proximal SVS was significantly associated with no early recanalization (odds ratio 16.80, 95% confidence interval 2.04-138.17, p = 0.009). Among the 95 patients with a premorbid mRS score of 0-1, none (0%) of the 16 patients with M1 proximal SVS, 5 (36%) of the 14 patients with M1 distal SVS, 12 (48%) of the 25 patients with MCA distal SVS, and 13 (33%) of the 40 patients with No SVS achieved a good outcome (p = 0.011, 1.000, and 0.295, respectively, compared to the patients with No SVS).
CONCLUSION: M1 proximal SVS on T2*-weighted MRI is a strong predictor for no early recanalization, and all patients with it had a poor outcome. However, M1 distal SVS and MCA distal SVS were not predictors for no early recanalization, and half of the patients had a poor outcome.

Entities:  

Keywords:  Acute ischemic stroke; Susceptibility vessel sign; Thrombolysis

Year:  2013        PMID: 24163686      PMCID: PMC3806703          DOI: 10.1159/000354848

Source DB:  PubMed          Journal:  Cerebrovasc Dis Extra        ISSN: 1664-5456


Introduction

The aim of the intravenous recombinant tissue plasminogen activator (t-PA) therapy for acute stroke is to recanalize the occluded artery and reperfuse the penumbral tissue. Early recanalization, defined as recanalization during the first 1-2 h of t-PA therapy, is expected to triple or quadruple the favorable outcome rate [1,2,3]. In patients without early recanalization, intra-arterial intervention is a promising approach. The RECANALISE (Recanalisation Using Combined Intravenous Alteplase and Neurointerventional Algorithm for Acute Ischemic Stroke) study showed that combined t-PA therapy and intra-arterial intervention was associated with higher recanalization than t-PA alone, and a better outcome was associated with time from symptom onset to recanalization [4]. We have recently reported that the susceptibility vessel sign (SVS) seen on T2*-weighted MRI as a hypointense signal at the proximal portion of the horizontal (M1) middle cerebral artery (MCA) served as the only independent factor related to no early recanalization and a poor outcome [5,6]. Thus, we considered that patients with M1 proximal SVS are exactly those who need immediate combined intravenous and intra-arterial treatment. In our previous reports, however, we did not evaluate the impact of the SVS at other locations, such as distal M1, the vertical portion (M2) of the MCA, and distal branches, on early recanalization and patient outcomes. Although some studies reported patients' characteristics and radiological findings based on different SVS sites [7], their effects on early recanalization and clinical outcome remain unknown. The aim of the present study was to investigate, whether the impact of the SVS on early recanalization and patient outcomes differs based on their MCA location in patients treated with t-PA.

Methods

Consecutive patients with acute ischemic stroke and treated with t-PA admitted to our stroke center between October 2005 and October 2012 were prospectively enrolled; t-PA therapy was generally administered based on the Japan Alteplase Clinical Trial [8,9]. In addition, in our hospital, acute ischemic stroke patients with unknown onset time were also treated with t-PA based on diffusion-weighted imaging (DWI)/fluid-attenuated inversion recovery (FLAIR) mismatch [10]. The interval from onset to t-PA therapy was automatically calculated as 180 min in those patients. Only patients with an occlusion of the internal carotid artery (ICA), M1, and M2 were enrolled in the present study. A single t-PA dose of 0.6 mg/kg (not exceeding 60 mg) was administered intravenously, with 10% given as a bolus, followed by a continuous infusion of the remainder of the dose over 1 h. The institutional Review Board at the Kawasaki Medical School approved this study. The following clinical information was obtained: age, sex, time from onset to treatment, neurological deficits, modified Rankin Scale (mRS) score before stroke, vascular risk factors, atrial fibrillation, past antithrombotic medication, blood pressure before intravenous thrombolysis, stroke etiology, and the presence of cardiac sources of emboli. Neurological deficits were assessed using the National Institutes of Health Stroke Scale (NIHSS) score before thrombolysis. Vascular risk factors were identified as: (1) hypertension, a history of using antihypertensive agents, a systolic blood pressure ≥140 mm Hg, or a diastolic blood pressure ≥90 mm Hg at hospital discharge; (2) diabetes mellitus, the use of hypoglycemics, random glucose level ≥200 mg/dl, or glycosylated hemoglobin >6.4% on admission, and (3) hyperlipidemia, the use of antihyperlipidemic agents or serum cholesterol level >220 mg/dl. Medications taken before admission were also documented. Anticoagulation was performed using warfarin sodium. Aspirin, ticlopidine, clopidogrel, and cilostazol were given as antiplatelet therapy. Stroke etiology was determined at hospital discharge using Trial of ORG 10172 in Acute Stroke Treatment criteria: (1) small-vessel occlusion, (2) large-artery atherosclerosis, (3) cardioembolism, or (4) other or undetermined etiology of stroke [11]. Duplex ultrasonography was performed in all patients to assess the common carotid artery and ICA. To determine the presence of cardiac sources of emboli, transcranial Doppler, transthoracic echocardiography, and Holter electrocardiography were also carried out. Transesophageal echocardiography and conventional cerebral angiography were performed if appropriate. The MRI protocol included DWI, FLAIR, T2*-weighted MRI, and intracranial MRA, which were performed on a 1.5-tesla scanner (Signa EXCITE XL v. 11.0; GE Healthcare, Milwaukee, Wis., USA) on admission and 1 h after t-PA administration. DWI was obtained using the following parameters: repetition time (TR), 6,000 ms; echo time (TE), 78 ms; b values, 0 and 1,000 s/mm2; field of view, 24 cm; acquisition matrix, 128 × 192, and slice thickness, 6.0 mm with a 1.0-mm gap. FLAIR sequences were obtained in the axial plane using the following parameters: TR, 8,002 ms; TE, 109 ms; inversion time, 2,000 ms; field of view, 24 cm; acquisition matrix, 256 × 224, and section thickness, 6.0 mm with a 1.0-mm gap. T2*-weighted images were obtained using the following parameters: TR, 700 ms; TE, 20 ms; field of view, 24 cm; acquisition matrix, 256 × 192, and section thickness, 6.0 mm with a 1.0-mm gap. Time-of-flight MRA covered the circle of Willis with: TR, 25 ms; TE, 6.9 ms, and flip angle, 20°. The SVS defined as a hypointense signal of the MCA on T2*-weighted MRI on admission was assessed by one vascular neurologist (J.A.) who was blinded to the clinical information. M1 proximal SVS was defined as an SVS at the origin of the M1. M1 distal SVS was any SVS not including the origin of the M1. MCA distal SVS was considered as an SVS further away from M1 (fig. 1). The Alberta Stroke Program Early CT Score on DWI on admission was also assessed. A semiquantitative evaluation using the Alberta Stroke Program Early CT Score on DWI has been shown to be a reproducible method similar to that on CT [12,13,14]. The infarct volume on the initial DWI was calculated using NIH image. First, the perimeter of the area of abnormal signal intensity was traced on each DWI image, and then the NIH image calculated the total volume using the thickness and the area delineated on the slice. The presence of recanalization was assessed using MRA 1 h after t-PA therapy. Recanalization was graded as complete, partial, or no recanalization as follows: (1) complete recanalization: reappearance of the entire occluded artery and distal branch of vessels; (2) partial recanalization: new appearance of at least one of the distal branches supplied by an occluded artery, and (3) no recanalization: persistent occlusion. For patients treated with intra-arterial intervention before follow-up MRI, digital subtraction angiography was used to assess recanalization. Early recanalization was evaluated before intra-arterial intervention started. Grade 2 and more according to the Thrombolysis in Cerebral Infarction grading system was defined as early recanalization [15].
Fig. 1

Representative cases with an SVS at the proximal (a) and distal portions of the horizontal (M1) MCA (b), and at the distal portion of the MCA (c, d).

At 3 months, the presence of a good outcome (mRS score, 0-1) was assessed.

Statistical Analysis

First, all patients were classified into 4 groups based on the presence and location of the SVS as follows: (1) M1 proximal SVS, (2) M1 distal SVS, (3) MCA distal SVS, and (4) No SVS. Clinical, radiological, and laboratory findings were compared among the 4 groups. Second, all patients were divided into 2 groups based on the presence and absence of early recanalization. Multivariate logistic regression analysis was used to identify independent factors associated with early recanalization. Variables from univariate analyses with p values <0.1 were entered into the multivariate analysis. The relative risk of early recanalization was expressed as odds ratios with 95% confidence intervals. After that, clinical outcomes were evaluated among the 4 groups. The Mann-Whitney U test was used to analyze differences in continuous variables, and Fisher's exact test was used to analyze differences in categorical variables. The data are presented as median values (interquartile ranges) or frequencies (%). All statistical analyses were performed using IBM SPSS Statistics for Windows version 19 software (Chicago, Ill., USA). Results were considered significant at p < 0.05.

Results

From October 2005 to October 2012, 266 patients were admitted to our hospital and treated with t-PA therapy. Of the 266 patients, 43 had ICA occlusion, 69 had M1 occlusion, and 46 had M2 occlusion. Thus, 158 patients [median age, 78 (71-84) years; 84 (53%) males; median NIHSS score, 16 (10-20)] were enrolled into the present study. Of the 158 patients, 23 (15%) underwent intra-arterial intervention, and of these 23 patients, the presence of early recanalization was assessed by digital subtraction angiography in 4. An SVS was seen in 91 (58%) of the 158 patients. M1 proximal SVS (M1 proximal group) was seen in 25 (16%) patients; M1 distal SVS (M1 distal group) in 22 (14%); MCA distal SVS (MCA distal group) in 44 (28%), and 67 (42%) patients did not have an SVS (No SVS group). The patients' clinical characteristics and imaging findings according to the SVS locations are shown in table 1. The NIHSS score of the M1 proximal group was the highest (p = 0.001). The incidence of hypertension was significantly different among the 4 groups (p = 0.037). Regarding the sites of arterial occlusions, ICA occlusion was frequent (72%) in the M1 proximal group (p < 0.001), M1 occlusion was frequent (86%) in the M1 distal group (p < 0.001), and M2 occlusion was frequent (52%) in the MCA distal group (p < 0.001). The No SVS group had ICA occlusion more frequently than the MCA distal group (27 vs. 9%, p = 0.028).
Table 1

Clinical characteristics and imaging findings based on the presence and location of the SVS

VariablesM1 proximal SVSM1 distal SVSMCA distal SVSNo SVSp
(n = 25)(n = 22)(n = 44)(n = 67)
Median age, years79 (73 – 83)76 (66 – 86)79 (74 – 84)77 (70 – 85)0.960
Male sex, n14 (56)15 (68)21 (48)34 (51)0.431
Median NIHSS score on admission20 (15 – 23)17 (12 – 22)13 (7 – 19)16 (10 – 20)0.001
Premorbid mRS score 0 – 1, n20 (75)18 (82)32 (73)49 (73)0.771
Interval from onset to thrombolysis, min153 (131 – 167)146 (120 – 167)145 (120 – 175)143 (115 – 172)0.894
Intra-arterial intervention, n4 (16)4 (18)5 (11)10 (15)0.887
Vascular risk factor, n
 Hypertension11 (44)14 (64)34 (77)47 (70)0.037
 Diabetes mellitus3 (12)3 (14)8 (18)18 (27)0.310
 Hyperlipidemia3 (12)6 (27)9 (21)15 (22)0.608
 Atrial fibrillation18 (72)14 (64)25 (57)35 (52)0.356
Past medication, n
 Antiplatelet therapy7 (28)6 (27)8 (18)19 (28)0.648
 Anticoagulation therapy4 (16)2 (9)5 (11)5 (8)0.666
Median systolic blood pressure, mm Hg152 (145 – 168)156 (138 – 167)147 (131 – 164)156 (139 – 170)0.334
Median diastolic blood pressure, mm Hg82 (68 – 95)81 (70 – 98)81 (70 – 91)84 (70 – 92)0.860
Stroke etiology, n
 Large-artery atherosclerosis4 (16)3 (14)2 (5)7 (10)0.430
 Cardioembolism18 (72)14 (64)28 (64)38 (57)0.587
 Other or undetermined3 (12)5 (23)14 (32)22 (33)0.205
Portion of occlusion, n
 ICA18 (72)3 (14)4 (9)18 (27)<0.001
 M17 (28)19 (86)17 (39)26 (39)<0.001
 M20 (0)0 (0)23 (52)23 (34)<0.001
DWI findings
 Median ASPECTS7 (3 – 9)7 (5 – 9)8 (6 – 10)8 (6 – 10)0.095
 Median initial ischemic volume, ml12.3 (4.0 – 56.3)13.2 (2.1 – 42.2)4.1 (1.0 – 21.5)7.1 (1.6 – 35.8)0.091
Early recanalization
 No24 (96)16 (73)25 (57)36 (54)<0.001
 Partial1 (4)5 (23)12 (27)19 (28)0.088
 Complete0 (0)1 (4)7 (16)12 (18)0.071
Clinical outcome at 3 months
 mRS score 0 – 1, n0/16 (0)5/14 (36)12/25 (48)13/40 (33)0.014

Figures in parentheses are percentages or interquartile ranges. M1 indicates the horizontal portion of the MCA, M2 the sylvian portion of the MCA. ASPECTS = Alberta Stroke Program Early Computed Tomography Score.

Early recanalization occurred in 57 (36%) patients (table 2). On univariate analysis, M1 proximal SVS was seen in 24 (24%) of the 101 patients with no early recanalization and in 1 (2%) of the 57 patients with early recanalization (p < 0.001). On the other hand, No SVS was more frequent in the early recanalization group than in the no early recanalization group (54 vs. 36%, p = 0.029). ICA occlusion was less frequently observed in patients in the early recanalization group than in those not in the early recanalization group (14 vs. 35%, p = 0.005).
Table 2

Clinical characteristics and imaging findings between patients with early recanalization and those with no early recanalization

VariablesEarly recanalization (n = 57)No early recanalization (n = 101)p
Median age, years78 (73– 84)78 (71 – 84)0.710
Male sex, n33 (58)51 (51)0.409
Median NIHSS score on admission15 (10 – 20)17 (11 – 20)0.420
mRS score 0 – 1, n41 (74)77 (76)0.848
Interval from onset to thrombolysis, min132 (113 – 166)153 (125 – 170)0.107
Intra-arterial intervention, n3 (5)20 (20)0.017
Susceptibility vessel sign, n
 M1 proximal1 (2)24 (24)<0.001
 M1 distal6 (11)16 (16)0.474
 MCA distal19 (33)25 (25)0.271
 No SVS31 (54)36 (36)0.029
Vascular risk factor, n
 Hypertension19 (33)33 (33)1.000
 Diabetes mellitus45 (79)81 (80)0.840
 Hyperlipidemia48 (84)77 (76)0.309
 Atrial fibrillation27 (47)39 (39)0.316
Past medication, n
 Antiplatelet therapy14 (25)26 (26)1.000
 Anticoagulation therapy5 (9)11 (11)0.788
Median systolic blood pressure, mm Hg132 (113 – 166)152 (136 – 167)0.406
Median diastolic blood pressure, mm Hg80 (70 – 90)84 (71 – 96)0.256
Stroke etiology, n
 Large-artery atherosclerosis2 (4)14 (14)0.053
 Cardioembolism32 (56)66 (65)0.306
 Other or undetermined23 (40)21 (21)0.010
Portion of occlusion, n
 ICA8 (14)35 (35)0.005
 M130 (53)39 (39)0.097
 M219 (33)27 (27)0.466
DWI findings
 Median ASPECTS8 (5 – 10)8 (6 – 9)0.828
 Median initial ischemic volume, ml5.6 (1.0 – 39.2)9.4 (1.9 – 37.2)0.588

Figures in parentheses are percentages or interquartile ranges. M1 indicates the horizontal portion of the MCA, M2 the sylvian portion of the MCA. ASPECTS = Alberta Stroke Program Early Computed Tomography Score.

The rates of no early recanalization among the 4 groups are shown in figure 2. Twenty-four (96%) of the 25 patients in the M1 proximal group, 16 (73%) of the 22 patients in the M1 distal group, 25 (57%) of the 44 patients in the MCA distal group, and 36 (54%) of the 67 patients in the No SVS group had no early recanalization (p < 0.001). The frequency of no early recanalization was significantly higher in the M1 proximal group than in the M1 distal group, the MCA distal group, and the No SVS group (p = 0.040, 0.001, and <0.001, respectively). On the other hand, the rate of no early recanalization in the M1 distal group was not different from that in the MCA distal group and in the No SVS group (p = 0.284 and 0.140, respectively). No significant difference in the rate of no early recanalization was seen between the MCA distal group and the No SVS group (p = 0.846).
Fig. 2

Incidences of no early recanalization based on the presence of the SVS.

Multivariate analysis showed that only M1 proximal SVS was significantly associated with no early recanalization after adjusting for M1 distal SVS, MCA distal SVS, stroke etiologies (large-artery atherosclerosis and other or undetermined), ICA occlusion, and M1 occlusion (odds ratio, 16.80; 95% confidence interval, 2.04-138.17; p = 0.009; table 3).
Table 3

Multivariate logistic regression analysis for factors associated with no early recanalization

ParametersOdds ratio95% Confidence intervalp
Susceptibility vessel sign
 M1 proximal16.802.04–138.170.009
 M1 distal2.930.92 – 9.340.070
 MCA distal1.230.55 – 2.790.615
Stroke etiology
 Large-artery atherosclerosis2.640.51 – 13.730.250
 Other or undetermined0.560.26 – 1.200.134
Portion of the arterial occlusion
 ICA1.210.39 – 3.710.744
 M10.60.26 – 1.410.242

M1 indicates the horizontal portion of the MCA.

At 3 months, 95 patients with premorbid mRS scores of 0-1 and without intra-arterial intervention were eligible for the assessment of clinical outcome (fig. 3). None (0%) of the M1 proximal group, 36% of the M1 distal group, 48% of the MCA distal group, and 33% of the No SVS group achieved good outcomes at 3 months (p = 0.014). Therefore, the M1 proximal group obtained a significantly lower rate of good outcome than the M1 distal group, the MCA distal group, and the No SVS group (p = 0.014, 0.001, and 0.011, respectively). However, no significant difference in the rate of good outcome was seen between the M1 distal group and the No SVS group, nor between the MCA distal group and the No SVS group (p = 1.000 and 0.295, respectively).
Fig. 3

Distribution of the mRS score at 3 months after stroke onset based on the presence of the SVS. Numbers of patients are given in the bars.

Discussion

The present study demonstrated that 96% of the patients with M1 proximal SVS had no early recanalization after t-PA therapy. Furthermore, no patients with M1 proximal SVS achieved a good outcome at 3 months. On the other hand, neither the rates of early recanalization nor good outcome was different among patients with M1 distal SVS, MCA distal SVS, and No SVS. Recently, we have reported that the presence of an SVS on T2*-weighted MRI was associated with resistance to t-PA therapy. The magnetic susceptibility effect of deoxygenated hemoglobin in red thrombi may result in hypointense signals on T2*-weighted MRI. Cho et al. [16] reported that red thrombi in occluded vessels were visualized as hypointense signals within vascular cisterns on T2*-weighted MRI. They called such radiological findings the ‘SVS’. The SVS may reflect thrombus composition. Hemoglobin desaturation from oxyhemoglobin to deoxyhemoglobin occurs within a few hours. Thus, in hyperacute clot cases, the main component may still be oxyhemoglobin, and such emboli would not be identified as SVS on T2*-weighted MRI. In other words, the SVS is present in older thrombi, which may be resistant to t-PA therapy. In the present study, the early recanalization rate of M1 distal SVS and MCA distal SVS was about 50%, which was higher than that of M1 proximal SVS. In general, when a small thrombus occludes the distal artery, the embolus volume of M1 proximal SVS may be largest among M1 proximal, M1 distal, and MCA distal SVS. When a thrombus is small, the proportion of the area in contact with t-PA becomes larger compared to a large thrombus, and thus t-PA may be more effective for smaller emboli. Therefore, M1 proximal SVS is the most resistant to t-PA, and its early recanalization rate should be the lowest. Early recanalization by t-PA administration can improve patient outcomes [2]. None of the patients with M1 proximal SVS achieved a good outcome 3 months after onset. We strongly presume that this is because t-PA cannot dissolve the M1 proximal SVS thrombus. Furthermore, the NIHSS score was higher in the M1 proximal group than in the other groups. Neurological severity before t-PA infusion affects patient outcome [17]. Therefore, patients with M1 proximal SVS most frequently had a poor outcome. After the Merci retriever and Penumbra aspiration systems were approved, the combination of t-PA therapy and intra-arterial intervention has attracted significant attention, because this combination therapy significantly increases the early recanalization rate [18,19]. In the RECANALISE study, 87% of the patients treated with the combined intravenous and intra-arterial approach achieved recanalization, compared to only 52% of the patients treated with t-PA alone [4]. With respect to medical therapy, we previously showed that the administration of edaravone, a free radical scavenger, during t-PA therapy might increase the incidence of early recanalization [20]. For patients with M1 proximal SVS, an immediate combination of these therapies may be of benefit, and this should be initiated before judging whether t-PA will be effective or not. No SVS did not necessarily indicate patients who achieved a good outcome, i.e. only 33% of the patients with No SVS had a good outcome. Our study showed that the rates of no early recanalization were not different among patients with M1 distal SVS, MCA distal SVS, and No SVS. Thus, this result may be explained by the ICA occlusion rate, which was higher in the order of patients with M1 proximal SVS, No SVS, M1 distal SVS, and MCA distal SVS. It is reasonable to consider that large-vessel occlusion damages larger tissue samples compared to small-vessel occlusion. There are several limitations in the present study. First, the number of patients was small. Second, our T2* protocol included a slice thickness of 6 mm and an interslice gap of 1 mm. If the artery was smaller than 6 mm, it may have been difficult to detect a small SVS, especially in the MCA branches. Third, our study did not include detailed information on occluded ICA segments. It was difficult to distinguish ICA top occlusion from ICA occlusion at other intracranial segments, when the patients showed a diminished flow signal. Even patients with proximal ICA occlusion might have tandem ICA top occlusion. This may be clarified only when CT angiography or digital subtraction angiography is performed. In addition, it also seems to be potentially difficult to discriminate a thrombus from the blood stream on T2*-weighted MRI [21]. Thus, artery occlusion must be diagnosed on MRA to assess the SVS. Finally, a 0.6-mg/kg dose of t-PA was used, based on the Japan Alteplase Clinical Trial [8]. If the internationally recommended dose had been selected, the role of M1 proximal SVS might have been different. Further, large, prospective, randomized trials are required to confirm the utility of M1 proximal SVS in patients treated with intravenous thrombolysis. In conclusion, M1 SVS at the proximal portion of the MCA, but not at other portions, is the critical determinant of no early recanalization and a poor outcome after t-PA therapy.

Disclosure Statement

The authors have no conflicts of interest to disclose.
  21 in total

1.  Predicting prognosis after stroke: a placebo group analysis from the National Institute of Neurological Disorders and Stroke rt-PA Stroke Trial.

Authors:  M R Frankel; L B Morgenstern; T Kwiatkowski; M Lu; B C Tilley; J P Broderick; R Libman; S R Levine; T Brott
Journal:  Neurology       Date:  2000-10-10       Impact factor: 9.910

2.  Significance of susceptibility vessel sign on T2*-weighted gradient echo imaging for identification of stroke subtypes.

Authors:  Kyung-Hee Cho; Jong S Kim; Sun U Kwon; A-Hyun Cho; Dong-Wha Kang
Journal:  Stroke       Date:  2005-10-13       Impact factor: 7.914

3.  Imaging of the brain in acute ischaemic stroke: comparison of computed tomography and magnetic resonance diffusion-weighted imaging.

Authors:  P A Barber; M D Hill; M Eliasziw; A M Demchuk; J H W Pexman; M E Hudon; A Tomanek; R Frayne; A M Buchan
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-11       Impact factor: 10.154

4.  Recanalization within one hour after intravenous tissue plasminogen activator is associated with favorable outcome in acute stroke patients.

Authors:  Kazumi Kimura; Yasuyuki Iguchi; Kensaku Shibazaki; Junya Aoki; Masao Watanabe; Kazuto Kobayashi; Yuki Sakamoto
Journal:  Eur Neurol       Date:  2010-06-03       Impact factor: 1.710

5.  Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.

Authors:  Randall T Higashida; Anthony J Furlan; Heidi Roberts; Thomas Tomsick; Buddy Connors; John Barr; William Dillon; Steven Warach; Joseph Broderick; Barbara Tilley; David Sacks
Journal:  Stroke       Date:  2003-07-17       Impact factor: 7.914

6.  Magnetic Resonance Imaging-DRAGON score: 3-month outcome prediction after intravenous thrombolysis for anterior circulation stroke.

Authors:  Guillaume Turc; Marion Apoil; Olivier Naggara; David Calvet; Catherine Lamy; Alina M Tataru; Jean-François Méder; Jean-Louis Mas; Jean-Claude Baron; Catherine Oppenheim; Emmanuel Touzé
Journal:  Stroke       Date:  2013-03-12       Impact factor: 7.914

7.  Timing of recanalization after intravenous thrombolysis and functional outcomes after acute ischemic stroke.

Authors:  Leonard L L Yeo; Prakash Paliwal; Hock L Teoh; Raymond C Seet; Bernard P L Chan; Shen Liang; Narayanaswamy Venketasubramanian; Rahul Rathakrishnan; Aftab Ahmad; Kay W P Ng; Pei K Loh; Jonathan J Y Ong; Benjamin R Wakerley; Vincent F Chong; Girish Bathla; Vijay K Sharma
Journal:  JAMA Neurol       Date:  2013-03-01       Impact factor: 18.302

8.  Comparison of intravenous alteplase with a combined intravenous-endovascular approach in patients with stroke and confirmed arterial occlusion (RECANALISE study): a prospective cohort study.

Authors:  Mikael Mazighi; Jean-Michel Serfaty; Julien Labreuche; Jean-Pierre Laissy; Elena Meseguer; Philippa C Lavallée; Lucie Cabrejo; Tarik Slaoui; Céline Guidoux; Bertrand Lapergue; Isabelle F Klein; Jean-Marc Olivot; Halim Abboud; Olivier Simon; Philippe Niclot; Chantal Nifle; Pierre-Jean Touboul; Gai Raphaeli; Christiane Gohin; Elisabeth Schouman Claeys; Pierre Amarenco
Journal:  Lancet Neurol       Date:  2009-07-31       Impact factor: 44.182

9.  Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.

Authors:  H P Adams; B H Bendixen; L J Kappelle; J Biller; B B Love; D L Gordon; E E Marsh
Journal:  Stroke       Date:  1993-01       Impact factor: 7.914

10.  Hyperacute ischemic stroke: middle cerebral artery susceptibility sign at echo-planar gradient-echo MR imaging.

Authors:  Alex Rovira; Patricia Orellana; Jose Alvarez-Sabín; Juan F Arenillas; Xavier Aymerich; Elisenda Grivé; Carlos Molina; Antoni Rovira-Gols
Journal:  Radiology       Date:  2004-06-23       Impact factor: 11.105

View more
  10 in total

1.  Susceptibility Vessel Sign on MRI Predicts Favorable Clinical Outcome in Patients with Anterior Circulation Acute Stroke Treated with Mechanical Thrombectomy.

Authors:  R Bourcier; S Volpi; B Guyomarch; B Daumas-Duport; A Lintia-Gaultier; C Papagiannaki; J M Serfaty; H Desal
Journal:  AJNR Am J Neuroradiol       Date:  2015-08-27       Impact factor: 3.825

2.  MRI Quantitative T2* Mapping to Predict Dominant Composition of In Vitro Thrombus.

Authors:  R Bourcier; R Pautre; M Mirza; C Castets; J Darcourt; J Labreuche; L Detraz; H Desal; J-M Serfaty; C Toquet
Journal:  AJNR Am J Neuroradiol       Date:  2019-01       Impact factor: 3.825

3.  Susceptibility Vessel Sign and Cardioembolic Etiology in the THRACE Trial.

Authors:  Romain Bourcier; Imad Derraz; Béatrice Delasalle; Marine Beaumont; Sebastien Soize; Laurence Legrand; Hubert Desal; Serge Bracard; Olivier Naggara; Catherine Oppenheim
Journal:  Clin Neuroradiol       Date:  2018-06-12       Impact factor: 3.649

4.  Susceptibility vessel sign predicts poor clinical outcome for acute stroke patients untreated by thrombolysis.

Authors:  Huiqin Liu; Wenli Mei; Yue Huang; Yongli Li; Zuzhi Chen; Dongdong Li; Hong Ye; Jiewen Zhang
Journal:  Exp Ther Med       Date:  2017-09-22       Impact factor: 2.447

5.  Validation of overestimation ratio and TL-SVS as imaging biomarker of cardioembolic stroke and time from onset to MRI.

Authors:  Romain Bourcier; Laurence Legrand; Sébastien Soize; Julien Labreuche; Marine Beaumont; Hubert Desal; Imad Derraz; Serge Bracard; Catherine Oppenheim; Olivier Naggara
Journal:  Eur Radiol       Date:  2018-11-12       Impact factor: 5.315

6.  Factors That Influence Susceptibility Vessel Sign in Patients With Acute Stroke Referred for Mechanical Thrombectomy.

Authors:  Manon Dillmann; Louise Bonnet; Fabrice Vuillier; Thierry Moulin; Alessandra Biondi; Guillaume Charbonnier
Journal:  Front Neurol       Date:  2022-05-11       Impact factor: 4.086

7.  Susceptibility Vessel Sign in the ASTER Trial: Higher Recanalization Rate and More Favourable Clinical Outcome after First Line Stent Retriever Compared to Contact Aspiration.

Authors:  Romain Bourcier; Mickael Mazighi; Julien Labreuche; Robert Fahed; Raphael Blanc; Benjamin Gory; Alain Duhamel; Gaultier Marnat; Suzana Saleme; Vincent Costalat; Serge Bracard; Hubert Desal; Arturo Consoli; Michel Piotin; Bertrand Lapergue
Journal:  J Stroke       Date:  2018-05-31       Impact factor: 6.967

8.  Middle cerebral artery thrombus susceptibility-weighted imaging mapping predicts prognosis.

Authors:  Mei-Zhu Zheng; Qing-Yuan Yang; Xiu-Di Lu; Si-Le Hu; Chao Chai; Wen Shen; Bin-Ge Chang; Zhi-Yun Wang; Shuang Xia
Journal:  Quant Imaging Med Surg       Date:  2019-09

9.  Susceptibility-Weighted Imaging for Detection of Thrombus in Acute Cardioembolic Stroke.

Authors:  Min-Gyu Park; Se-Jin Oh; Seung Kug Baik; Dae Soo Jung; Kyung-Pil Park
Journal:  J Stroke       Date:  2016-01-29       Impact factor: 6.967

Review 10.  ASL and susceptibility-weighted imaging contribution to the management of acute ischaemic stroke.

Authors:  Sébastien Verclytte; Olivier Fisch; Lucie Colas; Olivier Vanaerde; Manuel Toledano; Jean-François Budzik
Journal:  Insights Imaging       Date:  2016-11-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.